3 Things About NovoCure That Smart Investors Know
Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR), which makes a wearable device for treating cancer. The average investor might see NovoCure as yet another struggling cancer therapy company.
But smart investors see its less-appreciated advantages -- and also its lesser-known warts. So without further ado, let's dive in and think about three of the nuances that smart investors can see about this business.
1. It has no competitors -- or any on the horizon
The biggest thing that smart investors know about NovoCure is that it's pretty much the only business making wearable anti-cancer devices that deliver tumor-treating electromagnetic fields to patients to slow down the rate of tumor growth in aggressive cancers.
Its product, the Optune, is the only such device in the world, and it's approved in 10 countries, including the U.S., to help treat glioblastoma and mesothelioma as an add-on treatment to traditional modalities like chemotherapy. With the exception of Zai Lab, which licenses the Optune to commercialize it in Greater China, the rest of the world is NovoCure's oyster, which can't be said of many other cancer stocks.